Purpose: To study the safety, effects (good and bad), and anti-cancer activity of sacituzumab govitecan (Trodelvy®) antibody drug conjugate compared to standard of care chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received hormone therapy for advanced disease. You must have not yet received chemotherapy for advanced disease. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of BLU-222, an experimental targeted therapy, with fulvestrant (Faslodex®) hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer that progressed after treatment with a CDK 4/6 inhibitor. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ARV-471, an experimental hormone therapy, alone or with palbociclib (Ibrance®), a targeted therapy called a CDK 4/6 inhibitor.

Who is this for?: Postmenopausal women and men with locally advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have received hormone therapy for breast cancer and chemotherapy for advanced or metastatic disease. View full eligibility criteria

Purpose: To collect tumor samples that will be used to develop OncoPrism™, a test that helps providers predict response to immunotherapy.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) triple negative (ER-, PR-, HER2-) breast cancer who have received or are planning to receive treatment with a PD-1/PD-L1 inhibitor. You must have received a biopsy before beginning treatment with a PD-1/PD-L1 inhibitor. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of AZD9574, an experimental PARP inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer with a tumor or inherited BRCA1, BRCA2, PALB2, RAD51C, or RAD51D mutation. You must not have received treatment with a PARP inhibitor. You must have at least 1 tumor that has not been treated with radiation. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and best dose of DF1001 when it is given alone or with pembrolizumab (Keytruda®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer that tests HER2 1+, 2+ or 3+ on the IHC (immunohistochemistry) tumor test and have not had more than three lines of chemotherapy. View full eligibility criteria

Purpose: To study the dose, safety, side effects, and anti-cancer activity of giving the targeted therapies capivasertib and palbociclib (Ibrance®) with the anti-estrogen therapy fulvestrant (Faslodex®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer. Your cancer must have progressed on anti-estrogen therapy. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of OP-1250, an experimental hormone therapy, with ribociclib (Kisqali®) CDK 4/6 inhibitor or alpelisib (Piqray®) PI3K inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received 1-2 hormone therapies for advanced or metastatic disease. You must not have received more than 1 chemotherapy for advanced or metastatic disease. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of IDE161, a PARG inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with a BRCA1/2 mutation whose cancer has progressed on at least one previous therapy. View full eligibility criteria

Purpose: To create a registry to study metastatic lobular breast cancer, treatment patterns, and overall survival.

Who is this for?: People with stage IV (metastatic) lobular breast cancer. View full eligibility criteria

Purpose: To study if a mass response test can predict your cancer's response to potential treatments.

Who is this for?: People with stage I, stage II, stage III, or metastatic (stage IV) breast cancer that have malignant fluid. View full eligibility criteria

Purpose: To study if blood tests that look for tumor markers are as good as or better than imaging with PET and/or CT scans (the current standard of care) to determine if a tumor is growing.

Who is this for?: People with metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are planning to have first line treatment for metastatic disease or have started treatment within the past month, and have at least one elevated tumor marker. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of inavolisib, an experimental PI3K inhibitor, with fulvestrant (Faslodex®) hormone therapy compared to alpelisib (Piqray®) PI3K inhibitor with fulvestrant (Faslodex®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer with a PIK3CA mutation. You must have received treatment with a CDK 4/6 inhibitor with hormone therapy as 1 of up to 2 lines of therapy for advanced/metastatic disease. View full eligibility criteria

Purpose: To investigate whether a beta-blocker can help prevent heart problems caused by cancer treatments.

Who is this for?: People with metastatic (stage IV) HER2 positive (HER2+) breast cancer who are receiving or planning to receive trastuzumab (Herceptin®). View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of gedatolisib, an experimental pan-PI3K and mTOR inhibitor, with fulvestrant (Faslodex®) hormone therapy, with or without palbociclib (Ibrance®) CDK 4/6 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer with or without a PIK3CA mutation who have received treatment with a CDK 4/6 inhibitor with an aromatase inhibitor. You must not have received more than 1 chemotherapy for advanced disease or 2 lines of hormone therapy. View full eligibility criteria

Purpose: To compare the safety, effects (good and bad), and anti-cancer activity of ARV-471 (PF-07850327), an experimental hormone therapy, to fulvestrant (Faslodex®) hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have received 1 line of treatment with a CDK inhibitor with hormone therapy and up to 1 additional line of hormone therapy for advanced disease. You must not have received chemotherapy for advanced disease. View full eligibility criteria

Purpose: To study whether a PET/CT scan with 18F FES helps your doctor choose your next treatment.

Who is this for?: Women with metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) or HER2 low breast cancer that progressed after their first line of hormone therapy for metastatic disease. You must not have received more than 1 line of chemotherapy for metastatic disease. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of lasofoxifene, an experimental hormone therapy, with abemaciclib (Verzenio®) CDK4/6 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer with an ESR1 mutation. You must have received an aromatase inhibitor with palbociclib (Ibrance®) or ribociclib (Kisqali®) CDK4/6 inhibitor as your first line of hormone therapy for advanced disease. You must not have received more than 1 line of chemotherapy for advanced disease. View full eligibility criteria

Purpose: To collect patient reported outcomes (PRO) from people receiving trastuzumab deruxtecan (T-DXd, Enhertu®) antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) or HER2 low breast cancer who are planning to receive trastuzumab deruxtecan (T-DXd, Enhertu®) as their first or second line of therapy for advanced disease. You must have received anti-HER2 targeted therapy or chemotherapy. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ASTX727, an experimental DNA methyltransferase (DNMT) inhibitor, with paclitaxel (Taxol®) chemotherapy and pembrolizumab (Keytruda®) PD-1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of adding radiation to metastatic breast cancer treatment.

Who is this for?: People with metastatic (stage IV) oligoprogressive breast cancer who have received at least 1 line of therapy for metastatic disease. View full eligibility criteria

Purpose: To collect tissue samples, blood samples, and medical information from people with breast cancer to study how cancer changes over time and during treatment.

Who is this for?: People with stage III or stage IV (metastatic) breast cancer who are receiving or planning to receive treatment. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of giredestrant, an experimental hormone therapy, compared with fulvestrant (Faslodex®) hormone therapy in combination with a CDK4/6 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who not have received treatment (except for surgery or radiation) for advanced disease. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ribociclib (Kisqali®), trastuzumab (Herceptin®), and tucatinib (Tukysa®) targeted therapies alone or with fulvestrant (Faslodex®) hormone therapy.

Who is this for?: People with stage II, stage III, or stage IV (metastatic) HER2 positive (HER2+) or HER2 low breast cancer. If you have stage II or some stage III breast cancer, you must not have received treatment or surgery. If you have advanced (some stage III) or metastatic (stage IV) breast cancer, you must have received at least 1 line of anti-HER2 targeted therapy for metastatic disease. View full eligibility criteria

Purpose: To study where 68Ga-FAPi-46 and 68Ga-PSMA-11 accumulate in normal and cancer tissues and whether PET/CT scans with 68Ga-FAPi-46 and 68Ga-PSMA-11 can help locate cancer in the body.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive surgery to remove the primary tumor and/or metastasis. View full eligibility criteria

Purpose: To study the safety, effects, and best dose of Ceralasertib when it is used alone or with the chemotherapy carboplatin or the PARP inhibitor olaparib (Lynparza®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

Purpose: To study the safety, best dose and effects (good and bad) of NGM707 when given with and without Pembrolizumab (Keytruda®).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no other treatment options available. View full eligibility criteria

Purpose: To study the safety, best dose, and effects (good and bad) of NGM831, an experimental immunotherapy, alone and with pembrolizumab (Keytruda®) immunotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer that has progressed on standard treatment. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of tucatinib (Tukysa®), trastuzumab (Herceptin®) , and pertuzumab (Perjeta®) anti-HER2 targeted therapies compared to trastuzumab (Herceptin®) and pertuzumab (Perjeta®) alone.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer with and without evidence of disease. You must be receiving or have received treatment with trastuzumab (Herceptin®), pertuzumab (Herceptin®), and a taxane chemotherapy for advanced/metastatic disease. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of inavolisib, an experimental PI3K inhibitor, with Phesgo anti-HER2 targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer with a PIK3CA mutation who have not received treatment for advanced disease (except for hormone therapy if HR+). View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of palazestrant (OP-1250), an experimental hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer who have received a CDK4/6 inhibitor with hormone therapy for advanced disease. You must not have received chemotherapy or more than 2 lines of hormone therapy for advanced disease. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of ST316, an experimental Wnt/b-catenin inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer who have received 1-3 lines of therapy for advanced disease. View full eligibility criteria

Purpose: To look at the safety, best dose and effects of an experimental CAR T-cell immunotherapy that targets cancer cells that test positive for MUC1*, a special type of the MUC1 protein.

Who is this for?: People with metastatic (stage IV) breast cancer that tests positive for MUC1 and who have already received at least one standard therapy. View full eligibility criteria

Purpose: To study the anti-cancer activity and effects (good and bad) of giving radium-223 dichloride (a type of radiation therapy given by IV) in combination with paclitaxel (Taxol®).

Who is this for?: People with metastatic (stage IV), HER2 negative (HER2-) breast cancer that has spread to the bone and who have not received more than three lines of chemotherapy for metastatic disease. View full eligibility criteria

Purpose: To study the side effects (good and bad) of abemaciclib (Verzenio®).

Who is this for?: People with metastatic (stage IV), hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are age 70 or older and have already received treatment for metastatic disease. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of eftilagimod alpha, an experimental immunotherapy, with paclitaxel (Taxol®) chemotherapy.

Who is this for?: People with metastatic (stage IV) HER2 negative (HER2-) breast cancer who are planning to receive chemotherapy. You must not have yet received chemotherapy for metastatic disease. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ZN-A-1041, an experimental anti-HER2 targeted therapy, with other anti-HER2 targeted therapies.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) or HER2 low (IHC 2+) breast cancer who have no standard treatment options available. You must have received treatment with trastuzumab (Herceptin®) and chemotherapy. View full eligibility criteria

Purpose: To compare the safety and effects (good and bad) of camizestrant (AZD9833) and a CDK4/6 inhibitor with an aromatase inhibitor and a CDK4/6 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer and an ESR1 mutation. You must not have received treatment with fulvestrant (Faslodex®) or any investigational selective estrogen receptor degrader (SERD). View full eligibility criteria

Purpose: To study if WiseBag and CONCURxP mobile health tools will improve the ability of people to take their medication as prescribed compared to WiseBag alone.

Who is this for?: People with metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are planning to receive a CDK4/6 inhibitor or started receiving a CDK4/6 inhibitor within the past month. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of TBio-4101, an experimental tumor infiltrating lymphocyte (TIL) therapy, with pembrolizumab (Keytruda®) PD-1 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have received standard treatment. View full eligibility criteria

Purpose: To collect stool and blood samples to study gut microbiomes, study cancer biomarkers, and develop new treatments.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer planning to receive their next treatment. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of evexomostat (SDX-7320), an experimental polymer drug conjugate, with fulvestrant (Faslodex®) hormone therapy and alpelisib (Piqray®) PI3K inhibitor.

Who is this for?: Women with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer with a PIK3CA mutation who have high blood sugar. You must have received hormone therapy and a CDK 4/6 inhibitor. View full eligibility criteria

Purpose: To compare the ability of 3 regimens of dexamethasone, diphenhydramine (Benadryl®), and famotidine to prevent allergic reactions to paclitaxel (Taxol®) chemotherapy.

Who is this for?: Women with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive paclitaxel (Taxol®). View full eligibility criteria

Purpose: To study the safety, side effects, and antitumor activity of CPO-100, a taxane-based chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer that has already been treated with at least two lines of therapy. You must not have received a taxane-based chemotherapy for advanced cancer. View full eligibility criteria

Purpose: To look at the safety and effects (good and bad) of the combination of durvalumab (Imfinzi®) and paclitaxel (Taxol®) when used alone or with one of three additional therapies.

Who is this for?: Women with metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-) being treated for the first time for metastatic disease. View full eligibility criteria

Purpose: To study if providing women's health and fertility support helps women with breast cancer participate in oncofertility care aligning with their personal goals.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who live in Imperial County, California. View full eligibility criteria

Purpose: To study the safety and effects (good and bad) of romiplostim (Nplate®) for chemotherapy-induced thrombocytopenia.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are receiving or planning to receive chemotherapy. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of vepdegestrant, an experimental hormone therapy, with PF-07220060, an experimental CDK4 inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+) or ER low, HER2 negative (HER2-) breast cancer who have received a CDK4/6 inhibitor and at least 1 line of therapy for advanced disease. You must not have received more than 2 lines of hormone therapy or 1 line of chemotherapy for advanced disease. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of IMP1734, an experimental PARP inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have received chemotherapy and 0-1 lines of a PARP inhibitor. You must have a BRCA1, BRCA2, PALB2, ATM, ATR, CHEK2, FANCA, MLH1, MRE11A, NBN, RAD51C, CDK12, or other homologous recombination repair (HRR) mutation. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of NUV-1511, an experimental drug-drug conjugate (DDC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

Purpose: To study whether a PET/CT scan using a (18F) FES tracer is more effective at finding lobular breast cancer cells than the standard of care.

Who is this for?: People diagnosed with stage I, stage II or stage III lobular breast cancer within the last 3 months and who have not yet had surgery and people with stage IV (metastatic) lobular breast cancer diagnosed within the last 3 months View full eligibility criteria

Purpose: To study the ability of genomic testing and drug screening of tumor tissue to select your next treatment(s).

Who is this for?: People with metastatic (stage IV) HER2 negative (HER2-) breast cancer. If your cancer is triple negative (ER, PR-, HER2-), you must not have received treatment for metastatic disease. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of VIP236, an experimental small molecule drug conjugate (SMDC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have no standard treatment options available. View full eligibility criteria

Purpose: To use genetic testing to identify genetic mutations and make treatment decisions.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

Purpose: To collect and study blood and tissue samples and clinical data from people with newly diagnosed and untreated breast cancer, including inflammatory breast cancer.

Who is this for?: People with newly diagnosed and untreated stage I, stage II, stage III, or stage IV (metastatic) breast cancer. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of trastuzumab (Herceptin®) anti-HER2 targeted therapy, tucatinib (Tukysa®) tyrosine kinase inhibitor, and eribulin (Halaven®) chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) breast cancer who have received treatment with trastuzumab (Herceptin®) and chemotherapy for advanced/metastatic disease. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of AVA6000, an experimental chemotherapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer who have received standard treatment. View full eligibility criteria

Purpose: To study if sulfasalazine, an anti-inflammatory drug, can decrease pain and the use of opioid pain medication.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have experienced pain for at least 1.5 months and receive opioid pain medication. View full eligibility criteria

Purpose: To study the ability of losartan to decrease fibrosis from radiation.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, stage III, and stage IV (metastatic) breast cancer who have received surgery and are planning to receive radiation. Your breast cancer must not have recurred (came back), and you must not have received radiation. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of PF-07220060, an experimental CDK4 inhibitor, with fulvestrant (Faslodex®) hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received a CDK4/6 inhibitor with hormone therapy as the most recent line of therapy. You must not have received chemotherapy for advanced disease. View full eligibility criteria

Purpose: To identify the sexual health needs among women with breast cancer at the time of diagnosis and throughout treatment.

Who is this for?: Women with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have received care at the University of Colorado Hospital since September 2019. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of alpelisib (Piqray®) PI3K inhibitor and tucatinib (Tukysa) anti-HER2 targeted therapy with or without fulvestrant (Faslodex®) hormone therapy.

Who is this for?: People with metastatic (stage IV) HER2 positive (HER2+) breast cancer with a PIK3CA mutation who have received 2+ anti-HER2 targeted therapies. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ELVN-002, an experimental anti-HER2 targeted therapy, alone or with trastuzumab emtansine (Kadcyla®, T-DM1) antibody drug conjugate (ADC).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) HER2 positive (HER2+) or HER2 mutated breast cancer who have received at least 1 line of therapy for advanced/metastatic disease. View full eligibility criteria

Purpose: To improve ways of determining health risks of older adults with cancer, and to find better ways to address their needs.

Who is this for?: People at least 65 years old with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have not yet received treatment. View full eligibility criteria

Purpose: To determine how the immune system responds to different types of tumors or to tumors that develop during or after a pregnancy. Some of the breast cancer tissue collected in this study will be used to create models that develop and test new drug treatments.

Who is this for?: Women with any stage of breast cancer who are 50 years or younger View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of BGB-43395, an experimental CDK4 inhibitor, alone or with fulvestrant (Faslodex®) or letrozole (Femara®) hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who have received hormone therapy and a CDK4/6 inhibitor. You must not have received more than 2 lines of chemotherapy for advanced disease. View full eligibility criteria

Purpose: To study the safety, anti-cancer activity, and effects (good and bad) of giving the experimental therapy BT8009 alone or in combination with the PD-1 inhibitor nivolumab (Opdivo®).

Who is this for?: People with metastatic (stage IV) breast cancer that expresses Nectin-4 and who have no standard treatment options available. View full eligibility criteria

Purpose: To study if sulforaphane (Avmacol®) reduces heart problems caused by doxorubicin (Adriamycin®) chemotherapy.

Who is this for?: People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive doxorubicin (Adriamycin®) chemotherapy. You must not have received radiation to your chest, and if your tumor is HER2-positive, you must not be receiving trastuzumab (Herceptin®). View full eligibility criteria

Purpose: To learn more about the relationship between genetic mutations and cancer outcomes.

Who is this for?: People with inherited BRCA1/2 mutations or certain other genetic mutations (see list below) and people with stage I, stage II, stage III, or stage IV triple negative (ER-, PR-, HER2-) or ER Low (1%-10% ER) breast cancer. View full eligibility criteria

Purpose: To study the safety, anti-cancer activity and side effects of giving the experimental PARP inhibitor AZD5305 alone or with one or two chemotherapies.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer. View full eligibility criteria

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of ART6043, an experimental DNA polymerase theta inhibitor, with olaparib (Lynpara®) or talazoparib (Talzenna®) PARP inhibitor compared to a PARP inhibitor alone.

Who is this for?: People with advanced (stage III) or metastatic (stage IV) HER2 negative (HER2-) breast cancer with a BRCA1/2 mutation who have received treatment with paclitaxel (Taxol®), docetaxel (Taxotere®), or cabazitaxel (Jevtana®) chemotherapy. You must not have received more than 3 lines of chemotherapy including antibody drug conjugates (ADC) for advanced disease. View full eligibility criteria

Purpose: To study if low level vagus nerve stimulation will improve heart function.

Who is this for?: People at least 50 years old with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have received doxorubicin (Adriamycin®) and/or anti-HER2 targeted therapy within the last 3 months. You must also meet at least 1 of the following criteria: previous chest radiation, type 2 diabetes, high blood pressure, current smoker, obesity, and/or certain heart conditions. View full eligibility criteria

Purpose: To study the ability of GM1 to reduce or prevent nerve pain during treatment with paclitaxel (Taxol®) chemotherapy.

Who is this for?: People with metastatic (stage IV) breast cancer who are planning to receive treatment with paclitaxel (Taxol®) chemotherapy. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of ARTS-021, an experimental CDK2 inhibitor, alone or with other anti-cancer drugs.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ and/or PR+), HER2 negative (HER2-) or HER2 low breast cancer who have received a CDK4/6 inhibitor with hormone therapy for advanced disease. View full eligibility criteria

Purpose: To study the anti-cancer activity, safety, and side effects of giving the targeted therapy alpelisib (Piqray®) with an anti-hormone therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) hormone-positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer that tests positive for a PIK3CA mutation. In addition, you must have already received a CDK 4/6 inhibitor, and you must not have received more than two anti-hormone therapies for metastatic disease. View full eligibility criteria

Purpose: To study how trastuzumab emtansine (T-DM1, Kadcyla®) causes nerve pain in people with and without previous nerve pain.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) HER2 positive (HER2+) breast cancer who are planning to receive treatment with trastuzumab emtansine (T-DM1, Kadcyla®). View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of NM32-2668, an experimental trispecific antibody.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) ROR expressing breast cancer who have no standard treatment options available. View full eligibility criteria

Purpose: To investigate the safety, best dose and effects (good and bad) of ABBV-151 when it used with or without ABBV-181.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative breast cancer (ER-, PR- and HER2-) that has been treated with at least one systemic therapy. View full eligibility criteria

Purpose: To study the dose, safety, and side effects of giving the experimental targeted therapy APG2575 along with the CDK 4/6 inhibitor palbociclib (Ibrance®).

Who is this for?: People with metastatic (stage IV) estrogen-receptor positive (ER+), HER2-negative (HER2-) breast cancer who experienced disease progression while taking a CDK 4/6 inhibitor. View full eligibility criteria

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of EP0062, an experimental hormone therapy.

Who is this for?: Postmenopausal women with advanced (some stage III) or metastatic (stage IV) estrogen receptor positive (ER+), HER2 negative (HER2-) or HER2 low, androgen receptor positive (AR+) breast cancer with no standard treatment options available. View full eligibility criteria

Purpose: To study the anti-cancer activity, safety, and side effects of first giving bortezomib (Velcade®), then giving pembrolizumab (Keytruda®) and cisplatin (Platinol®).

Who is this for?: Women with metastatic (stage IV) triple negative (ER-, PR-, HER2-) or ER Low (1%-10% ER) breast cancer who have not received more than three chemotherapies for metastatic disease. View full eligibility criteria